Accelerate to discover

Back to filter

Related topics

Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer

Agilent technologies

Nov 23, 2021

Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...

Discover the advanced Detector Technology in Agilent NovoCyte flow cytometers

Agilent technologies

Nov 8, 2021

This technical overview describes advancements in detector technology, and highlights examples where optimal signal...

Jan 26, 2022

X-ray-virus-inactivation

Precision X-Ray

Oct 20, 2021

Ionizing radiation approaches are effective but use of radioactive radioisotopic elements have become difficult to...

Duke uses XRAD 225 CX to test radiosensitivity hypothesis

Precision X-Ray

Oct 18, 2021

Image guided radiotherapy in a preclinical setting couldn’t be more useful than the treatment of brain tumors, where...

Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing

Curiox

Oct 11, 2021

Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...

Jan 26, 2022

Falling in love with Magnetic resonance

Bruker Biospin

Oct 4, 2021

Magnetic Resonance (MR) is more than just analytical science, it is unique, it is a passion that won’t let you go

Show all topics (10)

Nanomedicine research relying on IZON products

Feb 23, 2016

InnoMedica, a Swiss nanomedicine company led by Dr. Peter Halbherr, is working towards developing a new nanocarrier platform to transport anti-cancer drugs directly to tumours, thereby avoiding the toxic effect of the drug on healthy cells. The platform will deliver existing active agents, initially Doxorubicin, encapsulated in liposomes.

The use of Doxorubicin in liposomes is well established and now off patent, being originally released as Doxil. InnoMedica’s innovative step is to attach glycans to the surface of the liposomes. Glycans are polymers of carbohydrates, also known as polysaccharides. As an imitation of the detection system of inflammation sites of the immune system, the patented glycan based targeting quickly brings the drug to the cancer site - resulting in a better efficacy, lower dosage and less side effects.

The team at InnoMedica is developing the targeting platform with a first application called Talidox (Targeted Liposomal Doxorubicin). With the release of this drug, InnoMedica aims to improve cancer treatment of many cancer patients receiving chemotherapy. Talidox is now in the preclinical phase; however, research results suggest that cancer patients should have access to Talidox soon.

The Talidox product is developed and produced in the company’s clean room in Marly, Switzerland. One of their first analytical instruments was Izon Science’s qNano. Since last year, researchers at InnoMedica use the qNano to measure the number, size and zeta potential of their liposomes. Unlike dynamic light scattering (DLS), Tunable Resistive Pulse Sensing (TRPS) allows researchers to accurately and simultaneously measure the size and the number of individual liposomes and to provide a real number based distribution. This enables product development and manufacture to be performed with confidence. Pascal Halbherr, InnoMedica’s Production Project Leader said “Getting the qNano into our lab was a turning point and allowed us to be certain about what we were actually producing”.

Application

Related technologies: Nano and micro particle analysis

Brand profile

IZON

IZON designs and manufactures precision instrumentation for nano- and micro-scaled particle analysis.

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey